Skip to main content

BioAge seeks nearly $200 million in initial public offering

The company is concentrating its aging diseases focus on weight loss and diabetes control.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.